1Laboratório de Imunologia Clínica - Faculdade de Medicina, Instituto de Medicina Molecular, Universidade de Lisboa
2Serviço de Imunoalergologia - Hospital Santa Maria - Centro Hospitalar Universitário Lisboa Norte
3 Clínica Universitária de Imunoalergologia - Faculdade de Medicina, Universidade de Lisboa
Published online: 15 January 2020
Accepted: 14 January 2020
Received: 15 November 2019
Background. Bee-venom (BV) anaphylaxis can be life-threatening, requiring treatment with BV immunotherapy (bVIT). Different molecular profiles may be associated with different outcomes after bVIT. Methods. In 19 patients with BV anaphylaxis, sensitized both to Api m1 and Api m10, we evaluated sIgE and sIgG4 Api m1 and Api m10 levels before and after 1 year bVIT. Results. 7 patients (37%) had higher baseline Api m10 than Api m1 sIgE levels (Api m10 predominant). bVIT reduced sIgE to both components but sIgG4 levels were increased only for Api m1. 5 patients (2 in the Api m10 predominant group) were re-stung without anaphylaxis. Conclusions. Although there was no increase in Api m10 sIgG4 levels after 1 year bVIT, we did not observe relevant differences in other outcomes between patients with predominant Api m1 or Api m10 sensitization.
Anaphylaxis; api m1; api m10; bee venom; Venom immunotherap